Soleus Capital Management, L.P. Terns Pharmaceuticals, Inc. Transaction History
Soleus Capital Management, L.P.
- $1.21 Billion
- Q1 2025
A detailed history of Soleus Capital Management, L.P. transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 8,167,100 shares of TERN stock, worth $36.3 Million. This represents 1.87% of its overall portfolio holdings.
Number of Shares
8,167,100
Previous 8,142,500
0.3%
Holding current value
$36.3 Million
Previous $45.4 Million
50.39%
% of portfolio
1.87%
Previous 3.16%
Shares
4 transactions
Others Institutions Holding TERN
# of Institutions
144Shares Held
84.6MCall Options Held
256KPut Options Held
133K-
Orbimed Advisors LLC San Diego, CA7.56MShares$33.7 Million0.65% of portfolio
-
Morgan Stanley New York, NY7.11MShares$31.6 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$30.7 Million5.17% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$24.8 Million0.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.15MShares$18.5 Million0.0% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $167M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...